HK1246685A1 - 治療或預防具有心肌梗塞病史的患者的動脈粥樣硬化血栓形成事件的方法 - Google Patents

治療或預防具有心肌梗塞病史的患者的動脈粥樣硬化血栓形成事件的方法

Info

Publication number
HK1246685A1
HK1246685A1 HK18106325.3A HK18106325A HK1246685A1 HK 1246685 A1 HK1246685 A1 HK 1246685A1 HK 18106325 A HK18106325 A HK 18106325A HK 1246685 A1 HK1246685 A1 HK 1246685A1
Authority
HK
Hong Kong
Prior art keywords
history
patients
prevention
treating
myocardial infarction
Prior art date
Application number
HK18106325.3A
Other languages
English (en)
Inventor
Robert Storey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55750410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1246685(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1246685A1 publication Critical patent/HK1246685A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18106325.3A 2015-01-27 2018-05-16 治療或預防具有心肌梗塞病史的患者的動脈粥樣硬化血栓形成事件的方法 HK1246685A1 (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562108453P 2015-01-27 2015-01-27
US201562112318P 2015-02-05 2015-02-05
US201562117871P 2015-02-18 2015-02-18
US201562133224P 2015-03-13 2015-03-13
US201562133327P 2015-03-14 2015-03-14
US201562156083P 2015-05-01 2015-05-01
US201562156823P 2015-05-04 2015-05-04
US201562211635P 2015-08-28 2015-08-28
PCT/IB2016/000275 WO2016120729A1 (en) 2015-01-27 2016-01-27 Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction

Publications (1)

Publication Number Publication Date
HK1246685A1 true HK1246685A1 (zh) 2018-09-14

Family

ID=55750410

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106325.3A HK1246685A1 (zh) 2015-01-27 2018-05-16 治療或預防具有心肌梗塞病史的患者的動脈粥樣硬化血栓形成事件的方法

Country Status (10)

Country Link
US (1) US10300065B2 (zh)
EP (2) EP3250207A1 (zh)
JP (3) JP2018502894A (zh)
CN (4) CN112402432A (zh)
AU (1) AU2016210973B2 (zh)
BR (1) BR112017015840A2 (zh)
CA (1) CA2974894A1 (zh)
HK (1) HK1246685A1 (zh)
RU (1) RU2707959C2 (zh)
WO (1) WO2016120729A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
WO2018167447A1 (en) 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US7695916B2 (en) 2007-03-22 2010-04-13 Celera Corporation Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof
EP2504705B1 (en) 2009-11-27 2017-04-12 Roche Diagnostics GmbH Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction
CN102058889A (zh) * 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
RU2469029C2 (ru) * 2010-12-30 2012-12-10 Закрытое Акционерное Общество "Вертекс" Вещество, обладающее сочетанной антиагрегантной, антикоагулянтной и вазодилаторной активностью, n,n'-замещенные пиперазины и способ их получения (варианты)
CN102731510B (zh) * 2011-04-07 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的衍生物、制备方法及其药物用途
CN102755336A (zh) * 2011-04-26 2012-10-31 符靠 包含格雷类药物和阿司匹林盐的药物组合物
CA2836394A1 (en) * 2011-06-01 2012-12-06 Astrazeneca Ab Novel ticagrelor co - crystal
CN102228691A (zh) * 2011-06-29 2011-11-02 北京阜康仁生物制药科技有限公司 阿司匹林和一种抗血小板药物的药物组合物
CN102406938A (zh) * 2011-11-29 2012-04-11 北京阜康仁生物制药科技有限公司 一种抗血栓的药物组合物
CN103664958B (zh) * 2012-09-26 2017-06-27 四川海思科制药有限公司 一种替卡格雷的晶型及其制备方法

Also Published As

Publication number Publication date
JP2020037564A (ja) 2020-03-12
BR112017015840A2 (pt) 2018-06-19
US20180015089A1 (en) 2018-01-18
CN112402432A (zh) 2021-02-26
CN112274519A (zh) 2021-01-29
JP2018502894A (ja) 2018-02-01
CN112402423A (zh) 2021-02-26
CN107530363A (zh) 2018-01-02
JP7523420B2 (ja) 2024-07-26
RU2017129068A3 (zh) 2019-03-04
AU2016210973A1 (en) 2017-08-31
AU2016210973B2 (en) 2019-02-14
RU2017129068A (ru) 2019-03-04
US10300065B2 (en) 2019-05-28
JP2022033919A (ja) 2022-03-02
EP3250207A1 (en) 2017-12-06
CA2974894A1 (en) 2016-08-04
WO2016120729A1 (en) 2016-08-04
RU2707959C2 (ru) 2019-12-03
EP3730142A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
HK1249030A1 (zh) 化合物及在治療衰老相關病症中的用途
IL284299A (en) Methods for treating inflammation or neuropathic pain
HK1248552A1 (zh) 使用川地匹坦的治療方法
HK1254954A1 (zh) Lpt-723和免疫檢查點抑制劑組合物及其治療方法
HK1259347A1 (zh) 治療結腸炎的方法
HK1263178A1 (zh) 檢測和治療生長激素缺乏症
PL3093358T3 (pl) Stal i sposób jej wytwarzania
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
HK1246685A1 (zh) 治療或預防具有心肌梗塞病史的患者的動脈粥樣硬化血栓形成事件的方法
GB201511799D0 (en) Composition and methods of treatment
HK1243961A1 (zh) 炎性病况的預防和治療
HUE064273T2 (hu) Eljárások iszap vízteleníthetõségének fokozására enzimes kezeléssel
ZA201608406B (en) Enzyme treatment composition
SI3259383T1 (sl) Kositer-nikljev sloj z visoko trdoto
GB2539474B (en) Glove and treatment method
GB201509420D0 (en) Composition and method
HK1244210A1 (zh) 人參皂苷m1用於預防或治療痛風的用途
GB201510870D0 (en) Treatment of infarction
HK1247817A1 (zh) 治療癌症及心肌梗塞的方法
ZA201608404B (en) Enzyme treatment composition
GB201518489D0 (en) Methods for the treatment and prevention of ebola
GB2586097B (en) Glove and treatment method
GB201415876D0 (en) Methods for the treatment and prevention of Ebola
GB201418526D0 (en) Kit and method for preventing or treating menopausal symptoms